MIHPC's report highlights major disparities in drug prices across Michigan hospitals, showcasing the urgent need for transparency and accountability.

Ustekinumab, a monoclonal antibody, is approved for the treatment of psoriasis vulgaris and psoriatic arthritis.

The Michigan Health Purchasers Coalition (MIHPC) has released three research reports highlighting perceived disparities in ...

Vermont hospitals are charging more than five times the average sales price for outpatient drugs — the highest markup in the ...

Bengaluru: Biocon Biologics Limited has announced that the Government of Malaysia has agreed to extend the current contract ...

Whereas filgrastim requires daily injections for about 14 days, pegfilgrastim requires one injection per chemotherapy cycle. Data from two pivotal Phase III trials in breast-cancer patients ...

Fresenius Kabi, an operating company of Fresenius, and Formycon AG, announced today that the U.S. Food and Drug Administration (FDA) designated Otulfi® (ustekinumab-aauz) as an interchangeable ...

A Michigan coalition urges patients and employers to compare hospital drug prices as new data reveals steep and unexplained ...

Napp’s Pelmeg, a biosimilar of Amgen’s cancer drug Neulasta (pegfilgrastim), has been launched in the UK following approval late last year. This is Napp’s first launch of a product developed ...